SCHEMBL172747

SCHEMBL172747

O=c1[nH]cc(-c2ccccc2)cc1-c1cc2ccccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.62
CHEK1 O14757 1/20 0.62
RAB9A P51151 4/20 0.56
NPC1 O15118 4/20 0.56
MAPT P10636 5/20 0.47
AURKA O14965 2/20 0.47
THRB P10828 1/20 0.47
CASP1 P29466 1/20 0.47
TTK P33981 1/20 0.47
AURKB Q96GD4 1/20 0.47
INCENP Q9NQS7 1/20 0.47
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
MCL1 Q07820 2/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
CASP3 P42574 2/20 0.43
SENP8 Q96LD8 2/20 0.43
SENP7 Q9BQF6 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025864 0.81 KDR (0.64) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL1414455 0.80 KDR (0.59) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL29370693 0.77 KDR (1.00) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL5076094 0.77 KDR (1.00) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL935681 0.75 KDR (0.65) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL10997079 0.74 RAB9A (0.71) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL11551230 0.74 KDM4E (0.68) KDRCHEK1RAB9ANPC1MAPT
SCHEMBL10997076 0.73 NPC1 (0.92) KDRCHEK1RAB9ANPC1MAPT
2-Phenyl-1H-Indole SCHEMBL29363616 0.73 NPC1 (1.00) KDRCHEK1RAB9ANPC1MAPT
2-Phenyl-1H-Indole SCHEMBL341378 0.73 NPC1 (1.00) KDRCHEK1RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340412-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood IOVANCE BIOTHERAPEUTICS INC (US) 2023-10-26 US disclosed
US-20230340412-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood IOVANCE BIOTHERAPEUTICS INC (US) 2023-10-26 US disclosed
US-20220118011-A1 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY IOVANCE BIOTHERAPEUTICS, INC. 2022-04-21 US disclosed
US-20200347350-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood IOVANCE BIOTHERAPEUTICS INC (US) 2020-11-05 US disclosed
US-20200224161-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF IOVANCE BIOTHERAPEUTICS, INC. 2020-07-16 US disclosed
EP-1919891-B1 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES VERTEX PHARMA (US) 2012-03-07 EP disclosed
US-7691885-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7691885-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-20070155794-A1 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-07-05 US disclosed
US-20070155794-A1 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-07-05 US disclosed
WO-2007027594-A1 3,5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200224161-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF PBK, MALT1, BCL9L KDR 293/4885CHEK1 2758/4885RAB9A 3244/4885
US-20230340412-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood LTK, LIFR, PBK KDR 99/4885CHEK1 3424/4885RAB9A 3473/4885
US-20200347350-A1 Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood LTK, LIFR, PBK KDR 99/4885CHEK1 3424/4885RAB9A 3473/4885
US-20070155794-A1 Pyridones useful as inhibitors of kinases MAP3K20, MAP3K6, MAP3K5 KDR 1496/4885CHEK1 106/4885RAB9A 2776/4885
US-20220118011-A1 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY ICOS, PBK, IL2 KDR 1379/4885CHEK1 3710/4885RAB9A 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.